Myriad Genetics

American biotechnology company

MYGN Nasdaq ISIN US62855J1043 SEC CIK 899923 LEI 52990044IHUOUMETT163
Follow Myriad Genetics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $202.7M −1.5% vs same quarter last year
Net income −$43.9M −60.2% vs same quarter last year
EPS, diluted −$0.46 −58.6% vs same quarter last year
Operating cash flow −$6.5M −130.8% vs same quarter last year
Revenue by quarter
$210.6M
$195.9M
$213.1M
$205.7M
$209.8M
$200.4M
$190.7M
$202.7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$500M$0$500M$1BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$824.5M−$366M
FY24$837.6M−$127M
FY23$753.2M−$263M
FY22$678.4M−$112M
FY21$690.6M−$27M
FY20$638.6M−$199.5M
FY19$851.1M$4.6M
FY18$743.7M$133.3M
FY17$728.7M$17.4M
FY16$740.5M$117.2M
FY15$722.5M$79.8M
FY14$778.2M$176.2M
FY13$613.2M$147.2M
FY12$496M$112.2M
FY11$402.1M$100.7M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−50%0%50%100%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2569.9%−47%−44.4%
FY2469.9%−14.7%−15.2%
FY2368.6%−34.2%−34.9%
FY2270.2%−20.7%−16.5%
FY21-−27.6%−3.9%
FY20-−36.3%−31.2%
FY19-0.9%0.5%
FY18-16.4%17.9%
FY1780.1%6%2.4%
FY1682.1%20.7%15.8%
FY1581.6%18.5%11%
FY1487.7%35.3%22.6%
FY1389.5%37.2%24%
FY1289.6%36.4%22.6%
FY1188.6%39.2%25%
Free cash flowOperating cash flow minus capital expenditure
−$200M−$100M$0$100M$200MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22−$151.6M
FY21$600K
FY20$50.5M
FY19$75.1M
FY18$107.5M
FY17$100.1M
FY16$161.3M
FY15$116.6M
FY14$175.9M
FY13$162.5M
FY12$132.4M
FY11$127M
Returned to shareholdersDividends paid and shares bought back
$0$100M$200M$300MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25-
FY24-
FY23-
FY22-
FY21$0
FY20$0
FY19$50M
FY18$0
FY17$31.6M
FY16$162.6M
FY15$210.7M
FY14$287.7M
FY13$146.3M
FY12$128.5M
FY11$200.5M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Myriad Genetics
  • Healthcare median
−100%−50%0%50%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearMyriad GeneticsHealthcare median
FY25−44.4%−30.6%
FY24−15.2%−47%
FY23−34.9%−58%
FY22−16.5%−80.4%
FY21−3.9%−71.8%
FY20−31.2%−62.2%
FY190.5%−46.2%
FY1817.9%−49.6%
FY172.4%−45.9%
FY1615.8%−36%
FY1511%−37.8%
FY1422.6%−35.5%
FY1324%−37.1%
FY1222.6%−29.1%
FY1125%−27.9%